Work

20: Higher CD34+ Cell Doses are Associated with Decreased Relapse Rates Following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation with Trends to Improved Disease-Free Survival

Year: 2008

Type: article

Abstract: Table 1HRp-valuesOS 10/10 HLA match (baseline) vs. others2.23 (95%CI: 1.46–3.43)0.0002 Lymphocyte dose in the graft (continuous)0.20 (95%CI: 0.05–0.64)0.005 MNC dose in the graft: p25 (baseline) vs. others1.34 (95%CI: 1.01–1.82)0.04DFS 10/10 HLA match (baseline) vs. others1.91 (95%CI: 1.28–2.87)0.001 Lymphocyte dose in the graft (continuous)0.35 (95%CI: 0.14–0.81)0.01 Good risk disease (baseline) vs. others1.73 (95%CI: 1.01–3.17)0.04Relapse CD34+ quartile: p25 (baseline) vs. others0.64 (95%CI: 0.47–0.88)0.01 Recipient age (continuous)1.02 (95%CI: 1.00–1.05)0.02TRM 10/10 HLA match (baseline) vs. others2.46 (95%CI: 1.44–4.30)0.001 Full-intensity (baseline) vs. reduced-intensity conditioning1.76 (95%CI: 1.03–3.10)0.04MNC: mononuclear cell. Open table in a new tab MNC: mononuclear cell.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2007.12.028